Medpace Holdings, Inc. $MEDP Stock Sold by GW&K Investment Management LLC

GW&K Investment Management LLC trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 5.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 163,875 shares of the company’s stock after selling 8,821 shares during the quarter. Medpace makes up 0.9% of GW&K Investment Management LLC’s holdings, making the stock its 14th biggest holding. GW&K Investment Management LLC owned about 0.59% of Medpace worth $102,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in MEDP. Novem Group boosted its holdings in Medpace by 1.0% in the third quarter. Novem Group now owns 2,127 shares of the company’s stock valued at $1,328,000 after acquiring an additional 22 shares during the last quarter. Fifth Third Wealth Advisors LLC lifted its position in shares of Medpace by 3.2% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 783 shares of the company’s stock worth $489,000 after purchasing an additional 24 shares during the period. Motley Fool Asset Management LLC lifted its position in shares of Medpace by 3.3% in the 3rd quarter. Motley Fool Asset Management LLC now owns 819 shares of the company’s stock worth $511,000 after purchasing an additional 26 shares during the period. Balefire LLC boosted its stake in shares of Medpace by 7.0% in the 3rd quarter. Balefire LLC now owns 443 shares of the company’s stock valued at $277,000 after purchasing an additional 29 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its stake in shares of Medpace by 3.9% in the 3rd quarter. Global Retirement Partners LLC now owns 778 shares of the company’s stock valued at $486,000 after purchasing an additional 29 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO August Troendle sold 21,966 shares of the stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the completion of the sale, the chief executive officer directly owned 338,225 shares of the company’s stock, valued at approximately $211,549,590.75. This represents a 6.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Stephen Ewald sold 1,245 shares of the firm’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $690.00, for a total value of $859,050.00. Following the transaction, the general counsel owned 19,098 shares in the company, valued at approximately $13,177,620. This trade represents a 6.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 234,078 shares of company stock worth $147,170,305. 20.50% of the stock is owned by corporate insiders.

Medpace Price Performance

Shares of Medpace stock opened at $633.98 on Friday. The business has a 50-day simple moving average of $634.13 and a 200 day simple moving average of $534.89. The firm has a market capitalization of $17.73 billion, a price-to-earnings ratio of 35.14, a PEG ratio of 2.51 and a beta of 1.12. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $693.97.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, topping analysts’ consensus estimates of $4.44 by $0.40. The company had revenue of $716.00 million for the quarter, compared to analyst estimates of $714.47 million. Medpace had a return on equity of 99.76% and a net margin of 18.24%. Medpace’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.86 earnings per share. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 18.06 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on MEDP. Jefferies Financial Group reissued a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Mizuho set a $730.00 price objective on Medpace in a research note on Friday, October 23rd. Royal Bank Of Canada upped their target price on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Barclays raised their target price on Medpace from $625.00 to $675.00 and gave the stock an “equal weight” rating in a research note on Friday, October 23rd. Finally, TD Cowen lifted their target price on Medpace from $492.00 to $673.00 and gave the stock a “hold” rating in a report on Friday, October 23rd. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $649.27.

Read Our Latest Research Report on Medpace

About Medpace

(Free Report)

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.

See Also

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.